LAURENT FAUCHIER

 PU-PH en Cardiologie, membre permanent d'EES
 

A/ Présentation des thèmes de recherche 

• Contribution à la création de l’équipe de recherche clinique au sein du service de cardiologie du CHRU de Tours avec études observationnelles, institutionnelles et industrielles dans les thématiques de la rythmologie, des thérapeutiques antithrombotiques et de l’insuffisance cardiaque.

•Mise en place au sein de l’EA7505 « Éducation Éthique Santé » (EES) de la thématique « Recherche cardiovasculaire à partir des bases de données médico-administratives ».

B/ Publications 

Principales publications internationales dans des revues avec comité de lecture.(1–119)

1. Bruere H, Fauchier L, Bernard Brunet A, et al. History of thyroid disorders in relation to clinical outcomes in atrial fibrillation. Am. J. Med. 2015;128:30–37.

2. Lip GYH, Clementy N, Pierre B, Boyer M, Fauchier L. The impact of associated diabetic retinopathy on stroke and severe bleeding risk in diabetic patients with atrial fibrillation: the loire valley atrial fibrillation project. Chest 2015;147:1103–1110.

3. Lip GYH, Clementy N, Pericart L, Banerjee A, Fauchier L. Stroke and major bleeding risk in elderly patients aged ≥75 years with atrial fibrillation: the Loire Valley atrial fibrillation project. Stroke 2015;46:143–150.

4. Providência R, Boveda S, Lambiase P, et al. Prediction of Nonarrhythmic Mortality in Primary Prevention Implantable Cardioverter-Defibrillator Patients With Ischemic and Nonischemic Cardiomyopathy. JACC Clin. Electrophysiol. 2015;1:29–37.

5. Fauchier L, Marijon E, Defaye P, et al. Effect of age on survival and causes of death after primary prevention implantable cardioverter-defibrillator implantation. Am. J. Cardiol. 2015;115:1415–1422.

6. Angoulvant D, Villejoubert O, Bejan-Angoulvant T, et al. Effect of Active Smoking on Comparative Efficacy of Antithrombotic Therapy in Patients With Atrial Fibrillation: The Loire Valley Atrial Fibrillation Project. Chest 2015;148:491–498.

7. Fauchier L, Angoulvant D, Lip GYH. The SAMe-TT2R2 score and quality of anticoagulation in atrial fibrillation: a simple aid to decision-making on who is suitable (or not) for vitamin K antagonists. Eur. Eur. Pacing Arrhythm. Card. Electrophysiol. J. Work. Groups Card. Pacing Arrhythm. Card. Cell. Electrophysiol. Eur. Soc. Cardiol. 2015;17:671–673.

8. Angoulvant D, Angoulvant TB, Fauchier L. Dual antiplatelet therapy after acute coronary syndrome: a cardiologist-based optimal decision. Heart Br. Card. Soc. 2015;101:832–833.

9. Garnier S, Hengstenberg C, Lamblin N, et al. Involvement of BAG3 and HSPB7 loci in various etiologies of systolic heart failure: Results of a European collaboration assembling more than 2000 patients. Int. J. Cardiol. 2015;189:105–107.

10. Stamboul K, Zeller M, Fauchier L, et al. Prognosis of silent atrial fibrillation after acute myocardial infarction at 1-year follow-up. Heart Br. Card. Soc. 2015;101:864–869.

11. Fauchier L, Greenlaw N, Ferrari R, et al. Use of Anticoagulants and Antiplatelet Agents in Stable Outpatients with Coronary Artery Disease and Atrial Fibrillation. International CLARIFY Registry. PloS One 2015;10:e0125164.

12. Philippart R, Brunet-Bernard A, Clementy N, et al. Prognostic value of CHA2DS2-VASc score in patients with “non-valvular atrial fibrillation” and valvular heart disease: the Loire Valley Atrial Fibrillation Project. Eur. Heart J. 2015;36:1822–1830.

13. Boriani G, Savelieva I, Dan G-A, et al. Chronic kidney disease in patients with cardiac rhythm disturbances or implantable electrical devices: clinical significance and implications for decision making-a position paper of the European Heart Rhythm Association endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. Eur. Eur. Pacing Arrhythm. Card. Electrophysiol. J. Work. Groups Card. Pacing Arrhythm. Card. Cell. Electrophysiol. Eur. Soc. Cardiol. 2015;17:1169–1196.

14. Fauchier L, Philippart R, Clementy N, et al. How to define valvular atrial fibrillation? Arch. Cardiovasc. Dis. 2015;108:530–539.

15. Fauchier L, Poli D, Olshansky B. The SAMe-TT2R2 score and quality of anticoagulation in AF: Can we predict which patient benefits from anticoagulation? Thromb. Haemost. 2015;114:657–659.

16. Fauchier L, Clementy N, Pelade C, Collignon C, Nicolle E, Lip GYH. Patients With Ischemic Stroke and Incident Atrial Fibrillation: A Nationwide Cohort Study. Stroke 2015;46:2432–2437.

17. Fauchier L, Lecoq C, Clementy N, et al. Oral Anticoagulation and the Risk of Stroke or Death in Patients With Atrial Fibrillation and One Additional Stroke Risk Factor: The Loire Valley Atrial Fibrillation Project. Chest 2016;149:960–968.

18. Chen J, Dagres N, Hocini M, et al. Catheter ablation for atrial fibrillation: results from the first European Snapshot Survey on Procedural Routines for Atrial Fibrillation Ablation (ESS-PRAFA) Part II. Eur. Eur. Pacing Arrhythm. Card. Electrophysiol. J. Work. Groups Card. Pacing Arrhythm. Card. Cell. Electrophysiol. Eur. Soc. Cardiol. 2015;17:1727–1732.

19. Stamboul K, Fauchier L, Gudjoncik A, et al. New insights into symptomatic or silent atrial fibrillation complicating acute myocardial infarction. Arch. Cardiovasc. Dis. 2015;108:598–605.

20. Wilkoff BL, Fauchier L, Stiles MK, et al. 2015 HRS/EHRA/APHRS/SOLAECE Expert Consensus Statement on Optimal Implantable Cardioverter-Defibrillator Programming and Testing: Developed in partnership with and endorsed by the European Heart Rhythm Association (EHRA), the Asia Pacific Heart Rhythm Society (APHRS), and the Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLAECE)-Latin American Society of Cardiac Pacing and Electrophysiology. Endorsed by the American College of Cardiology (ACC) and American Heart Association (AHA). Eur. Eur. Pacing Arrhythm. Card. Electrophysiol. J. Work. Groups Card. Pacing Arrhythm. Card. Cell. Electrophysiol. Eur. Soc. Cardiol. 2015.

21. Wilkoff BL, Fauchier L, Stiles MK, et al. 2015 HRS/EHRA/APHRS/SOLAECE Expert Consensus Statement on Optimal Implantable Cardioverter-Defibrillator Programming and Testing. Heart Rhythm Off. J. Heart Rhythm Soc. 2015.

22. Ancedy Y, Lecoq C, Saint Etienne C, et al. Antithrombotic management in patients with atrial fibrillation undergoing coronary stent implantation: What is the impact of guideline adherence? Int. J. Cardiol. 2016;203:987–994.

23. Fauchier L, Samson A, Chaize G, et al. Cause of death in patients with atrial fibrillation admitted to French hospitals in 2012: a nationwide database study. Open Heart 2015;2:e000290.

24. Cotté F-E, Chaize G, Gaudin A-F, Samson A, Vainchtock A, Fauchier L. Burden of stroke and other cardiovascular complications in patients with atrial fibrillation hospitalized in France. Eur. Eur. Pacing Arrhythm. Card. Electrophysiol. J. Work. Groups Card. Pacing Arrhythm. Card. Cell. Electrophysiol. Eur. Soc. Cardiol. 2015.

25. Ascoeta MS, Marijon E, Defaye P, et al. Impact of early complications on outcomes in patients with implantable cardioverter-defibrillator for primary prevention. Heart Rhythm 2016;13:1045–1051.

26. Diamantopoulos A, Sawyer LM, Lip GY, et al. Cost-effectiveness of an insertable cardiac monitor to detect atrial fibrillation in patients with cryptogenic stroke. Int. J. Stroke Off. J. Int. Stroke Soc. 2016;11:302–312.

27. Darwiche W, Bejan-Angoulvant T, Dievart F, Babuty D, Angoulvant D, Fauchier L. Bleeding risk in patients treated with dabigatran or vitamin K antagonist for atrial fibrillation: A meta analysis of adjusted analysis in routine practice settings. Int. J. Cardiol. 2016;206:89–92.

28. Philippart R, Brunet-Bernard A, Clementy N, et al. CHA2DS2-VASc Score for Predicting Stroke and Thromboembolism in Patients With AF and Biological Valve Prosthesis. J. Am. Coll. Cardiol. 2016;67:343–344.

29. Philippart R, Brunet-Bernard A, Clementy N, et al. Oral anticoagulation, stroke and thromboembolism in patients with atrial fibrillation and valve bioprosthesis. The Loire Valley Atrial Fibrillation Project. Thromb. Haemost. 2016;115:1056–1063.

30. Providência R, Marijon E, Lambiase PD, et al. Primary Prevention Implantable Cardioverter Defibrillator (ICD) Therapy in Women-Data From a Multicenter French Registry. J. Am. Heart Assoc. 2016;5.

31. Wilkoff BL, Fauchier L, Stiles MK, et al. 2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. J. Arrhythmia 2016;32:1–28.

32. Fauchier L, Laborie G, Clementy N, Babuty D. Beta-blockers or Digoxin for Atrial Fibrillation and Heart Failure? Card. Fail. Rev. 2016;2:35–39.

33. Pericart L, Fauchier L, Bourguignon T, et al. Long-Term Outcome and Valve Surgery for Infective Endocarditis in the Systematic Analysis of a Community Study. Ann. Thorac. Surg. 2016;102:496–504.

34. Lip GYH, Fauchier L, Freedman SB, et al. Atrial fibrillation. Nat. Rev. Dis. Primer 2016;2:16016.

35. Fauchier L, Chaize G, Gaudin A-F, Vainchtock A, Rushton-Smith SK, Cotté F-E. Predictive ability of HAS-BLED, HEMORR2HAGES, and ATRIA bleeding risk scores in patients with atrial fibrillation. A French nationwide cross-sectional study. Int. J. Cardiol. 2016;217:85–91.

36. Fauchier L, Clementy N, Bisson A, et al. Should Atrial Fibrillation Patients With Only 1 Nongender-Related CHA2DS2-VASc Risk Factor Be Anticoagulated? Stroke 2016;47:1831–1836.

37. Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary. Eur. Heart J. 2017;38:2137–2149.

38. Garcia B, Clementy N, Benhenda N, et al. Mortality After Atrioventricular Nodal Radiofrequency Catheter Ablation With Permanent Ventricular Pacing in Atrial Fibrillation: Outcomes From a Controlled Nonrandomized Study. Circ. Arrhythm. Electrophysiol. 2016;9.

39. Perrin T, Mechulan A, Boveda S, et al. Does defibrillation testing influence outcomes after CRT-D implantation? A cause-of-death analysis from the DAI-PP study. Int. J. Cardiol. 2016;221:951–956.

40. Fauchier L, Lecoq C, Ancedy Y, et al. Evaluation of 5 Prognostic Scores for Prediction of Stroke, Thromboembolic and Coronary Events, All-Cause Mortality, and Major Adverse Cardiac Events in Patients With Atrial Fibrillation and Coronary Stenting. Am. J. Cardiol. 2016;118:700–707.

41. Fauchier L, Villejoubert O, Clementy N, et al. Causes of Death and Influencing Factors in Patients with Atrial Fibrillation. Am. J. Med. 2016;129:1278–1287.

42. Fauchier L, Bisson A, Lip GYH. Response by Fauchier et al to Letter Regarding Article, “Should Atrial Fibrillation Patients With Only 1 Nongender-Related CHA2DS2-VASc Risk Factor Be Anticoagulated?” Stroke 2016;47:e239.

43. Piccini JP, Fauchier L. Rhythm control in atrial fibrillation. Lancet Lond. Engl. 2016;388:829–840.

44. Providência R, Boveda S, Defaye P, et al. Outcome of Primary Prevention Implantable Cardioverter Defibrillator Therapy According to New York Heart Association Functional Classification. Am. J. Cardiol. 2016;118:1225–1232.

45. Fauchier L, Ruiz-Nodar JM, Valdés M, Angoulvant D, Lip GYH, Marín F. Is oral anticoagulation needed in patients with atrial fibrillation and stent implantation at low-moderate risk of stroke? Eur. J. Intern. Med. 2016;35:e9–e10.

46. Darwiche W, Bejan-Angoulvant T, Angoulvant D, Babuty D, Fauchier L. Risk of myocardial infarction and death in patients with atrial fibrillation treated with dabigatran or vitamin K antagonists. Meta-analysis of observational analyses. Thromb. Haemost. 2016;116:1150–1158.

47. Fauchier L, Alonso C, Anselme F, et al. Position paper for management of elderly patients with pacemakers and implantable cardiac defibrillators: Groupe de Rythmologie et Stimulation Cardiaque de la Société Française de Cardiologie and Société Française de Gériatrie et Gérontologie. Arch. Cardiovasc. Dis. 2016;109:563–585.

48. Fauchier L, Alonso C, Anselme F, et al. Position paper for management of elderly patients with pacemakers and implantable cardiac defibrillators Groupe de rythmologie et stimulation cardiaque de la Société française de cardiologie et Société française de gériatrie et gérontologie. Geriatr. Psychol. Neuropsychiatr. Vieil. 2016;14:239–264.

49. Clementy N, Benhenda N, Piver E, et al. Serum Galectin-3 Levels Predict Recurrences after Ablation of Atrial Fibrillation. Sci. Rep. 2016;6:34357.

50. Fauchier L, Clementy N, Bisson A, et al. Prognosis in patients with atrial fibrillation and a presumed “temporary cause” in a community-based cohort study. Clin. Res. Cardiol. Off. J. Ger. Card. Soc. 2017;106:202–210.

51. Reek S, Burri H, Roberts PR, et al. The wearable cardioverter-defibrillator: current technology and evolving indications. Eur. Eur. Pacing Arrhythm. Card. Electrophysiol. J. Work. Groups Card. Pacing Arrhythm. Card. Cell. Electrophysiol. Eur. Soc. Cardiol. 2017;19:335–345.

52. Gorenek Chair B, Pelliccia Co-Chair A, Benjamin EJ, et al. European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS). Eur. J. Prev. Cardiol. 2017;24:4–40.

53. Fauchier L, Bisson A, Clementy N. Prognosis in Familial Atrial Fibrillation. J. Am. Heart Assoc. 2016;5.

54. Potpara TS, Dagres N, Mujović N, et al. Decision-Making in Clinical Practice: Oral Anticoagulant Therapy in Patients with Non-valvular Atrial Fibrillation and a Single Additional Stroke Risk Factor. Adv. Ther. 2017;34:357–377.

55. Clementy N, Challal F, Marijon E, et al. Very high rate programming in primary prevention patients with reduced ejection fraction implanted with a defibrillator: Results from a large multicenter controlled study. Heart Rhythm 2017;14:211–217.

56. Fauchier L, Bisson A, Clementy N. ICD Implantation in Patients with Nonischemic Heart Failure. N. Engl. J. Med. 2017;376:89–90.

57. Amara N, Boveda S, Defaye P, et al. Implantable cardioverter-defibrillator therapy among patients with non-ischaemic vs. ischaemic cardiomyopathy for primary prevention of sudden cardiac death. Eur. Eur. Pacing Arrhythm. Card. Electrophysiol. J. Work. Groups Card. Pacing Arrhythm. Card. Cell. Electrophysiol. Eur. Soc. Cardiol. 2018;20:65–72.

58. Gorenek B, Pelliccia A, Benjamin EJ, et al. European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS). Eur. Eur. Pacing Arrhythm. Card. Electrophysiol. J. Work. Groups Card. Pacing Arrhythm. Card. Cell. Electrophysiol. Eur. Soc. Cardiol. 2017;19:190–225.

59. Boveda S, Narayanan K, Jacob S, et al. Temporal Trends Over a Decade of Defibrillator Therapy for Primary Prevention in Community Practice. J. Cardiovasc. Electrophysiol. 2017;28:666–673.

60. Defaye P, Boveda S, Klug D, et al. Dual- vs. single-chamber defibrillators for primary prevention of sudden cardiac death: long-term follow-up of the Défibrillateur Automatique Implantable-Prévention Primaire registry. Eur. Eur. Pacing Arrhythm. Card. Electrophysiol. J. Work. Groups Card. Pacing Arrhythm. Card. Cell. Electrophysiol. Eur. Soc. Cardiol. 2017;19:1478–1484.

61. Pericart L, Bernard A, Bourguignon T, et al. Comparison of Outcome of Possible Versus Definite Infective Endocarditis Involving Native Heart Valves. Am. J. Cardiol. 2017;119:1854–1861.

62. Bernard A, Menet A, Marechaux S, et al. Predicting Clinical and Echocardiographic Response After Cardiac Resynchronization Therapy With a Score Combining Clinical, Electrocardiographic, and Echocardiographic Parameters. Am. J. Cardiol. 2017;119:1797–1802.

63. Fauchier L, Pericart L, Bourguignon T, et al. Prediction of Systemic Septic Embolism in Patients With Left-Sided Infective Endocarditis. J. Am. Coll. Cardiol. 2017;69:1992–1993.

64. Freedman B, Camm J, Calkins H, et al. Screening for Atrial Fibrillation: A Report of the AF-SCREEN International Collaboration. Circulation 2017;135:1851–1867.

65. Bisson A, Angoulvant D, Philippart R, Clementy N, Babuty D, Fauchier L. Non-Vitamin K Oral Anticoagulants for Stroke Prevention in Special Populations with Atrial Fibrillation. Adv. Ther. 2017;34:1283–1290.

66. Deng H, Bai Y, Shantsila A, Fauchier L, Potpara TS, Lip GYH. Clinical scores for outcomes of rhythm control or arrhythmia progression in patients with atrial fibrillation: a systematic review. Clin. Res. Cardiol. Off. J. Ger. Card. Soc. 2017;106:813–823.

67. Clementy N, Laborie G, Pierre B, Benhenda N, Babuty D, Fauchier L. Three-dimensional interlead distance predicts response and outcomes after cardiac resynchronization therapy. Arch. Cardiovasc. Dis. 2017;110:590–598.

68. Escande W, Boveda S, Defaye P, et al. Outcomes in Guideline-Based Versus Off-Guideline Primary Prevention Implantable Cardioverter-Defibrillator Recipients. J. Am. Coll. Cardiol. 2017;70:1302–1303.

69. Bisson A, Clementy N, Bodin A, et al. Relationship of Preexisting Cardiovascular Comorbidities to Newly Diagnosed Atrial Fibrillation After Ischemic Stroke. Stroke 2017;48:2878–2880.

70. Lip GYH, Coca A, Kahan T, et al. Hypertension and cardiac arrhythmias: a consensus document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE). Eur. Eur. Pacing Arrhythm. Card. Electrophysiol. J. Work. Groups Card. Pacing Arrhythm. Card. Cell. Electrophysiol. Eur. Soc. Cardiol. 2017;19:891–911.

71. Fauchier L, Pericart L, Bourguignon T, et al. Comparison of Outcome of Possible Versus Definite Infective Endocarditis Involving Prosthetic or Bioprosthetic Heart Valves. Am. J. Cardiol. 2017;120:1884–1890.

72. Gorenek B, Bax J, Boriani G, et al. Device-detected subclinical atrial tachyarrhythmias: definition, implications and management-an European Heart Rhythm Association (EHRA) consensus document, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE). Eur. Eur. Pacing Arrhythm. Card. Electrophysiol. J. Work. Groups Card. Pacing Arrhythm. Card. Cell. Electrophysiol. Eur. Soc. Cardiol. 2017;19:1556–1578.

73. Guenancia C, Garnier F, Mouhat B, et al. [Screening and clinical implications of silent atrial fibrillation]. Rev. Med. Interne 2018;39:574–579.

74. Bai Y, Guo S-D, Deng H, et al. Effectiveness and safety of oral anticoagulants in older patients with atrial fibrillation: a systematic review and meta-regression analysis. Age Ageing 2018;47:9–17.

75. Boriani G, Proietti M, Laroche C, et al. Contemporary stroke prevention strategies in 11 096 European patients with atrial fibrillation: a report from the EURObservational Research Programme on Atrial Fibrillation (EORP-AF) Long-Term General Registry. Eur. Eur. Pacing Arrhythm. Card. Electrophysiol. J. Work. Groups Card. Pacing Arrhythm. Card. Cell. Electrophysiol. Eur. Soc. Cardiol. 2018;20:747–757.

76. Mairesse GH, Moran P, Van Gelder IC, et al. Screening for atrial fibrillation: a European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLAECE). Eur. Eur. Pacing Arrhythm. Card. Electrophysiol. J. Work. Groups Card. Pacing Arrhythm. Card. Cell. Electrophysiol. Eur. Soc. Cardiol. 2017;19:1589–1623.

77. Lip GYH, Collet JP, Caterina R de, et al. Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE). Eur. Eur. Pacing Arrhythm. Card. Electrophysiol. J. Work. Groups Card. Pacing Arrhythm. Card. Cell. Electrophysiol. Eur. Soc. Cardiol. 2017;19:1757–1758.

78. Sarkozy A, De Potter T, Heidbuchel H, et al. Occupational radiation exposure in the electrophysiology laboratory with a focus on personnel with reproductive potential and during pregnancy: A European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS). Eur. Eur. Pacing Arrhythm. Card. Electrophysiol. J. Work. Groups Card. Pacing Arrhythm. Card. Cell. Electrophysiol. Eur. Soc. Cardiol. 2017;19:1909–1922.

79. Lip GYH, Collet JP, de Caterina R, et al. Antithrombotic Therapy in Atrial Fibrillation Associated with Valvular Heart Disease: Executive Summary of a Joint Consensus Document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, Endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE). Thromb. Haemost. 2017;117:2215–2236.

80. Defaye P, Klug D, Anselme F, et al. Recommendations for the implantation of leadless pacemakers from the French Working Group on Cardiac Pacing and Electrophysiology of the French Society of Cardiology. Arch. Cardiovasc. Dis. 2018;111:53–58.

81. Fauchier L, Bisson A, Genet T. Antiplatelet therapy, vitamin K antagonist and low time in therapeutic range in patients with atrial fibrillation: Highway to bleed. Int. J. Cardiol. 2018;252:110–111.

82. Bisson A, Bodin A, Clementy N, Babuty D, Lip GYH, Fauchier L. Prediction of Incident Atrial Fibrillation According to Gender in Patients With Ischemic Stroke From a Nationwide Cohort. Am. J. Cardiol. 2018;121:437–444.

83. Fauchier L, Bisson A, Angoulvant D. Rivaroxaban in Stable Cardiovascular Disease. N. Engl. J. Med. 2018;378:395.

84. Bisson A, Bodin A, Clementy N, et al. Stroke, thromboembolism and bleeding in patients with atrial fibrillation according to the EHRA valvular heart disease classification. Int. J. Cardiol. 2018;260:93–98.

85. Steffel J, Verhamme P, Potpara TS, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur. Heart J. 2018;39:1330–1393.

86. Steffel J, Verhamme P, Potpara TS, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. Eur. Eur. Pacing Arrhythm. Card. Electrophysiol. J. Work. Groups Card. Pacing Arrhythm. Card. Cell. Electrophysiol. Eur. Soc. Cardiol. 2018;20:1231–1242.

87. Dagres N, Chao T-F, Fenelon G, et al. European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on arrhythmias and cognitive function: what is the best practice? Eur. Eur. Pacing Arrhythm. Card. Electrophysiol. J. Work. Groups Card. Pacing Arrhythm. Card. Cell. Electrophysiol. Eur. Soc. Cardiol. 2018;20:1399–1421.

88. Dagres N, Chao T-F, Fenelon G, et al. European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on arrhythmias and cognitive function: what is the best practice? Heart Rhythm 2018;15:e37–e60.

89. Gorenek B, Boriani G, Dan G-A, et al. European Heart Rhythm Association (EHRA) position paper on arrhythmia management and device therapies in endocrine disorders, endorsed by Asia Pacific Heart Rhythm Society (APHRS) and Latin American Heart Rhythm Society (LAHRS). Eur. Eur. Pacing Arrhythm. Card. Electrophysiol. J. Work. Groups Card. Pacing Arrhythm. Card. Cell. Electrophysiol. Eur. Soc. Cardiol. 2018;20:895–896.

90. Bongiorni MG, Burri H, Deharo JC, et al. 2018 EHRA expert consensus statement on lead extraction: recommendations on definitions, endpoints, research trial design, and data collection requirements for clinical scientific studies and registries: endorsed by APHRS/HRS/LAHRS. Eur. Eur. Pacing Arrhythm. Card. Electrophysiol. J. Work. Groups Card. Pacing Arrhythm. Card. Cell. Electrophysiol. Eur. Soc. Cardiol. 2018;20:1217.

91. Clementy N, Piver E, Bisson A, et al. Galectin-3 in Atrial Fibrillation: Mechanisms and Therapeutic Implications. Int. J. Mol. Sci. 2018;19.

92. Bourguignon T, Bernard A, Fauchier L. Risk of Thromboembolic Events without Oral Anticoagulation at 90 Days after Surgical Aortic Valve Replacement with a Bioprosthesis. Thromb. Haemost. 2018;118:945–947.

93. Fauchier L, Cinaud A, Brigadeau F, et al. Device-Related Thrombosis After Percutaneous Left Atrial Appendage Occlusion for Atrial Fibrillation. J. Am. Coll. Cardiol. 2018;71:1528–1536.

94. Providencia R, Marijon E, Barra S, et al. Usefulness of a clinical risk score to predict the response to cardiac resynchronization therapy. Int. J. Cardiol. 2018;260:82–87.

95. Bisson A, Bodin A, Fauchier L. Why and how to screen for atrial fibrillation. Heart Br. Card. Soc. 2018;104:1474–1475.

96. Fauchier L, Bisson A, Clementy N, et al. Changes in glomerular filtration rate and outcomes in patients with atrial fibrillation. Am. Heart J. 2018;198:39–45.

97. Dagres N, Chao T-F, Fenelon G, et al. European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on arrhythmias and cognitive function: What is the best practice? J. Arrhythmia 2018;34:99–123.

98. Clementy N, Bisson A, Challal F, et al. Nonsustained Ventricular Tachycardia at the Time of Implantation Predicts Appropriate Therapies on Rapid Ventricular Arrhythmia in Primary Prevention Patients With Nonischemic Cardiomyopathy: Results From the Very-High-Rate Registry. JACC Clin. Electrophysiol. 2017;3:1338–1339.

99. Boriani G, Fauchier L, Aguinaga L, et al. European Heart Rhythm Association (EHRA) consensus document on management of arrhythmias and cardiac electronic devices in the critically ill and post-surgery patient, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Cardiac Arrhythmia Society of Southern Africa (CASSA), and Latin American Heart Rhythm Society (LAHRS). Eur. Eur. Pacing Arrhythm. Card. Electrophysiol. J. Work. Groups Card. Pacing Arrhythm. Card. Cell. Electrophysiol. Eur. Soc. Cardiol. 2019;21:7–8.

100. Linde C, Bongiorni MG, Birgersdotter-Green U, et al. Sex differences in cardiac arrhythmia: a consensus document of the European Heart Rhythm Association, endorsed by the Heart Rhythm Society and Asia Pacific Heart Rhythm Society. Eur. Eur. Pacing Arrhythm. Card. Electrophysiol. J. Work. Groups Card. Pacing Arrhythm. Card. Cell. Electrophysiol. Eur. Soc. Cardiol. 2018;20:1565–1565ao.

101. Clementy N, Fourquet A, Andre C, et al. Benefits of an early management of palpitations. Medicine (Baltimore) 2018;97:e11466.

102. Fauchier L, Cinaud A, Brigadeau F, Lepillier A, Defaye P. Reply: Device-Related Thrombus After Percutaneous Left Atrial Appendage Occlusion in Patients With Atrial Fibrillation. J. Am. Coll. Cardiol. 2018;72:474–475.

103. Lip GYH, Collet J-P, Haude M, et al. 2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA). Eur. Eur. Pacing Arrhythm. Card. Electrophysiol. J. Work. Groups Card. Pacing Arrhythm. Card. Cell. Electrophysiol. Eur. Soc. Cardiol. 2019;21:192–193.

104. Guenancia C, Toucas C, Fauchier L, et al. High rate of recurrence at long-term follow-up after new-onset atrial fibrillation during acute myocardial infarction. Eur. Eur. Pacing Arrhythm. Card. Electrophysiol. J. Work. Groups Card. Pacing Arrhythm. Card. Cell. Electrophysiol. Eur. Soc. Cardiol. 2018;20:e179–e188.

105. Clementy N, Garcia B, André C, et al. Galectin-3 level predicts response to ablation and outcomes in patients with persistent atrial fibrillation and systolic heart failure. PloS One 2018;13:e0201517.

106. Dallongeville J, Sacher F, Bouée S, et al. Xafran, a drug utilization study of rivaroxaban in stroke prevention in atrial fibrillation in France using a claim database. Therapie 2018;73:449–460.

107. Algalarrondo V, Perault R, Bories M-C, et al. Prophylactic implantable cardioverter defibrillators for primary prevention: From implantation to heart transplantation. Arch. Cardiovasc. Dis. 2018;111:758–765.

108. Zannad F, Anker SD, Byra WM, et al. Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease. N. Engl. J. Med. 2018;379:1332–1342.

109. Maury P, Defaye P, Klug D, et al. Position paper concerning the competence, performance and environment required in the practice of complex ablation procedures. Arch. Cardiovasc. Dis. 2019;112:67–73.

110. Briere J-B, Bowrin K, Coleman C, et al. Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with vitamin K antagonists in patients with nonvalvular atrial fibrillation: a systematic literature review. Expert Rev. Pharmacoecon. Outcomes Res. 2018:1–10.

111. Chao T-F, Fauchier L. Stroke prevention in patients with atrial flutter: many questions still unanswered. Eur. Eur. Pacing Arrhythm. Card. Electrophysiol. J. Work. Groups Card. Pacing Arrhythm. Card. Cell. Electrophysiol. Eur. Soc. Cardiol. 2019;21:186–187.

112. Fauchier L, Bisson A, Clementy N. Alcohol and Cardiac Structure: Less Is Better. J. Am. Coll. Cardiol. 2018;72:1463–1465.

113. Bisson A, Pucheux J, Andre C, et al. Localization of Left Ventricular Lead Electrodes in Relation to Myocardial Scar in Patients Undergoing Cardiac Resynchronization Therapy. J. Am. Heart Assoc. 2018;7:e009502.

114. Andre C, Piver E, Perault R, et al. Galectin-3 predicts response and outcomes after cardiac resynchronization therapy. J. Transl. Med. 2018;16:299.

115. Fauchier L, Cinaud A, Brigadeau F, et al. Left Atrial Appendage Closure in Atrial Fibrillation. J. Am. Coll. Cardiol. 2018;72:2806–2807.

116. Fauchier L, Bodin A, Bisson A. Editorial commentary: The CHA2DS2VASc score and its black and white items. Trends Cardiovasc. Med. 2018.

117. Clementy N, Ancedy Y, Bisson A, et al. Distal-to-proximal delay for ablation of premature ventricular contractions. J. Cardiovasc. Electrophysiol. 2019;30:205–211.

118. Fauchier L, Clementy N, Bisson A. Wearable Cardioverter–Defibrillator after Myocardial Infarction. N. Engl. J. Med. 2019;380:600.

119. Coleman CI, Briere J-B, Fauchier L, et al. Meta-analysis of real-world evidence comparing non-vitamin K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation. J. Mark. Access Health Policy 2019;7:1574541

C/ Colloques, conférences et communications 

  • 45 communications en 1er ou dernier auteur dans les congrès internationaux de cardiologie de l’ESC, ACC AHA et EHRA.
  • Conférencier ou Modérateur invité régulier dans ces congrès

D/ Recherches et interventions 

  • Membre du comité scientifique et d’organisation de l’étude EORP-AF : EurObservational Research Programme - Atrial Fibrillation Long-Term
  • Membre du comité de validation des évènements de l’étude internationale EAST Early treatment of Atrial fibrillation for Stroke prevention Trial (EAST)

E/ Responsabilités scientifiques et pédagogiques 

  • Expert reviewer pour Archives des Maladies du Coeur et des Vaisseaux, Annales de Cardiologie et d’Angéiologie, The American Journal of Cardiology, American Journal of Hypertension, American Journal of Physiology - Heart and Circulatory Physiology, Circulation, Coronary Artery Disease, Critical Care Medicine, Europace, Journal of the American College of Cardiology, Journal of Applied Physiology, European Heart Journal, Heart, Obesity Research, The Lancet, Thrombosis Haemostasis.
  • 2013-2018 : EHRA : European Heart Rhythm Association : membre puis vice chairman du comité de rédaction des documents scientifiques (2016-2018)
  • Membre élu du bureau du Groupe de Rythmologie de la SFC, Président élu pour la période 2020-2021.
  • Responsable de l’enseignement de Cardiologie en deuxième cycle universitaire (DFASM1, 4ème année de Médecine) de la Faculté de Médecine de TOURS depuis 2011
  • Coordonnateur et responsable pédagogique en troisième cycle universitaire pour le Diplôme d'Etudes Spécialisées en Pathologie Cardio-Vasculaire pour la subdivision de la Faculté de Médecine de TOURS
  • Responsable en troisième cycle universitaire pour le Diplôme Universitaire «DIU Prévention-réadaptation cardiovasculaires » créé en 2011 avec les Universités de TOURS, PARIS V, PARIS VII.